Alaa Kubbar, MD
Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1528598943
Payments from drug & device makers
Across 183 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$771
- Lilly USA, LLC$593
- Amgen$474
- Corcept Therapeutics$412
- AstraZeneca$274
- Bayer$176
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,294100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $771 |
| Lilly USA, LLC | 24 | $593 |
| Amgen(2 entities) | 20 | $474 |
| Corcept Therapeutics | 9 | $412 |
| AstraZeneca(2 entities) | 12 | $274 |
| Bayer | 10 | $176 |
| Sanofi-aventis U.S. LLC | 3 | $176 |
| Sequel Med Tech, LLC | 2 | $144 |
| Xeris Pharmaceuticals, Inc. | 6 | $128 |
| AbbVie | 7 | $119 |
| Kyowa Kirin, Inc. | 5 | $113 |
| Novartis | 7 | $111 |
| Medtronic | 5 | $103 |
| Tandem Diabetes Care, Inc. | 5 | $100 |
| Mannkind Corporation | 4 | $91 |
| Boehringer Ingelheim | 4 | $86 |
| Amneal Pharmaceuticals LLC | 3 | $73 |
| Ascendis Pharma Endocrinology Inc | 2 | $53 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Abbott | 2 | $45 |
| Merck | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $25 |
| RGH Enterprises LLC | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $22 |
| Dexcom, Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,314 in reported general payments places this provider in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 441 | $571,734 |
| JardianceEmpagliflozin | 404 | $452,106 |
| MounjaroTirzepatide | 131 | $240,652 |
| TrulicityDulaglutide | 130 | $202,791 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 48 | $74,302 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $73,007 |
| Tresiba Flextouch U-100Insulin Degludec | 92 | $67,738 |
| RybelsusSemaglutide | 29 | $59,567 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 64 | $57,911 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $50,776 |
| JanuviaSitagliptin Phosphate | 46 | $46,131 |
| Humalog Kwikpen U-100Insulin Lispro | 131 | $45,366 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 91 | $42,140 |
| FarxigaDapagliflozin Propanediol | 38 | $41,075 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 203 | $28,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $771 | $639,322491 claims |
| Boehringer IngelheimJardiance, Tradjenta | $86 | $469,535433 claims |
| Lilly USA, LLCMounjaro, Trulicity | $593 | $443,443261 claims |
| MerckJanuvia | $40 | $46,13146 claims |
| AstraZenecaFarxiga | $274 | $41,07538 claims |
| AbbVieSynthroid | $119 | $5,21961 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $73 | $4,849403 claims |
| Sanofi-aventis U.S. LLCLantus | $176 | $2,11219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Fall River
- Tamer YacoubFall River$1.4M
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.